Cellectar Biosciences, Inc.
CLRB
$0.2515
$0.00732.99%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -4.23% | -10.62% | -48.83% | -89.45% | -34.53% |
| Total Depreciation and Amortization | 51.53% | 82.39% | 74.23% | 61.41% | 29.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -123.31% | -73.46% | 68.69% | 571.40% | 41.94% |
| Change in Net Operating Assets | -149.65% | -106.20% | -272.38% | -83.85% | 106.44% |
| Cash from Operations | -46.97% | -53.23% | -55.01% | -40.88% | -28.37% |
| Capital Expenditure | 87.94% | 56.70% | -625.60% | -351.89% | -282.18% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 87.94% | 56.70% | -625.60% | -351.89% | -282.18% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 167.71% | 92.63% | 594.95% | 594.95% | 138.69% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 167.71% | 92.63% | 594.95% | 594.95% | 138.69% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 233.22% | 1,171.91% | 205.41% | 252.35% | 34.96% |